Additional Information
Book Details
Abstract
This issue of Hospital Medicine Clinics, edited by Dr. Eddy Chen, covers topics including: Being the Oncology Hospitalist; Caring for Acute Leukemics; Blood Transfusions for Cancer Patients; QI Initiatives in Hospitalized Cancer Patients; Febrile Neutropenia - A Closer Look; Chemotherapy Complications - Short and Long Term Issues; Malignant Bowel Obstruction; Tumor Lysis Syndrome; Principles of Radiation Therapy: What Hospitalists Need to Know; and Neoplastic Related Cord Compression.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover\r | Cover | ||
| Contributors | A1 | ||
| CONSULTING EDITOR | A1 | ||
| EDITOR | A1 | ||
| AUTHORS | A1 | ||
| Contents | A3 | ||
| Preface\r | A3 | ||
| Being an Oncology Hospitalist\r | A3 | ||
| Acute Leukemia\r | A3 | ||
| Blood Transfusions for Hospitalized Patients with Cancer\r | A3 | ||
| Quality and Safety in Hospitalized Patients with Cancer\r | A3 | ||
| Infectious Complications of Solid Tumor Malignancy\r | A4 | ||
| Chemotherapy Complications\r | A4 | ||
| Malignant Bowel Obstruction in Advanced Cancer\r | A4 | ||
| Tumor Lysis Syndrome\r | A4 | ||
| Principles of Radiation Therapy: What Hospitalists Need to Know\r | A5 | ||
| Metastatic Spinal Cord Compression: Presentation, Diagnosis, and Management\r | A5 | ||
| HOSPITAL MEDICINE CLINICS\r | A6 | ||
| FORTHCOMING ISSUES | A6 | ||
| October 2016 | A6 | ||
| January 2017 | A6 | ||
| RECENT ISSUES | A6 | ||
| April 2016 | A6 | ||
| January 2016 | A6 | ||
| October 2015 | A6 | ||
| Preface | A7 | ||
| Being an Oncology Hospitalist | 335 | ||
| KEY PRINCIPLES | 336 | ||
| Definitions | 336 | ||
| Background | 336 | ||
| Value-added domains | 337 | ||
| Current domains of waste | 338 | ||
| GUIDELINES FOR PRACTICE | 338 | ||
| Clinical Management Concepts | 338 | ||
| Current Challenges and Future Perspectives | 342 | ||
| Models | 343 | ||
| ACKNOWLEDGMENTS | 344 | ||
| REFERENCES | 344 | ||
| Acute Leukemia | 347 | ||
| BACKGROUND | 348 | ||
| MANAGEMENT | 349 | ||
| ACUTE MYELOID LEUKEMIA | 350 | ||
| Patients Less than 60 Years of Age | 350 | ||
| Patients More than 60 Years of Age | 351 | ||
| Role of Stem Cell Transplant in Acute Myeloid Leukemia | 351 | ||
| ACUTE PROMYELOCYTIC LEUKEMIA | 351 | ||
| ACUTE LYMPHOID LEUKEMIA | 351 | ||
| Febrile Neutropenia | 352 | ||
| Deep Venous Thrombosis Prophylaxis | 352 | ||
| Leukostasis | 352 | ||
| Differentiation Syndrome in Acute Promyelocytic Leukemia | 352 | ||
| Disseminated Intravascular Coagulation in Acute Promyelocytic Leukemia | 353 | ||
| Chemotherapy Side Effects | 353 | ||
| PERFORMANCE IMPROVEMENT | 353 | ||
| CLINICAL GUIDELINES | 354 | ||
| REFERENCES | 354 | ||
| Blood Transfusions for Hospitalized Patients with Cancer | 356 | ||
| BACKGROUND | 357 | ||
| CLINICAL GUIDELINES | 357 | ||
| Thoracentesis and Paracentesis | 358 | ||
| TRANSFUSION REACTIONS | 359 | ||
| OTHER TRANSFUSION COMPLICATIONS | 359 | ||
| Transfusion-related Sepsis | 359 | ||
| Transfusion-related Immune Modulation | 360 | ||
| Iron Overload | 361 | ||
| Refractoriness to Platelet Transfusion | 361 | ||
| PRECAUTIONS WITH BLOOD PRODUCTS | 361 | ||
| Leukoreduced and Cytomegalovirus Safe | 361 | ||
| Irradiated | 361 | ||
| Washed | 361 | ||
| OTHER BLOOD PRODUCTS/AGENTS | 362 | ||
| Granulocyte Colony-stimulating Factor | 362 | ||
| Granulocyte Infusions | 362 | ||
| Donor Lymphocyte Infusions | 363 | ||
| SPECIAL PATIENT POPULATIONS | 363 | ||
| PRACTICE IMPROVEMENT | 364 | ||
| REFERENCES | 364 | ||
| Quality and Safety in Hospitalized Patients with Cancer | 368 | ||
| KEY PRINCIPLES | 369 | ||
| GUIDELINES FOR PRACTICE: FALLS | 371 | ||
| GUIDELINES FOR PRACTICE: VENOUS THROMBOEMBOLISM | 372 | ||
| GUIDELINES FOR PRACTICE: INTENSIVE CARE UNIT TRANSFERS | 373 | ||
| GUIDELINES FOR PRACTICE: CENTRAL LINE–ASSOCIATED BLOODSTREAM INFECTIONS | 375 | ||
| SUMMARY | 376 | ||
| REFERENCES | 377 | ||
| Infectious Complications of Solid Tumor Malignancy | 379 | ||
| EPIDEMIOLOGY | 380 | ||
| PATHOPHYSIOLOGY | 381 | ||
| INFECTIOUS COMPLICATIONS OF BREAST CANCER | 381 | ||
| Epidemiology | 381 | ||
| Pathogens | 382 | ||
| Clinical Findings | 383 | ||
| Management | 383 | ||
| INFECTIOUS COMPLICATIONS OF LUNG CANCER | 384 | ||
| Epidemiology | 384 | ||
| Pathogens | 384 | ||
| Clinical Findings | 385 | ||
| Management | 386 | ||
| INFECTIOUS COMPLICATIONS OF UROLOGIC CANCERS | 387 | ||
| Renal Cell Carcinoma | 387 | ||
| Epidemiology | 387 | ||
| Pathogens | 387 | ||
| Clinical findings | 387 | ||
| Management | 388 | ||
| Prostate Cancer | 388 | ||
| Epidemiology | 388 | ||
| Pathogens | 388 | ||
| Clinical findings | 389 | ||
| Management | 389 | ||
| Bladder Cancer | 389 | ||
| Epidemiology | 389 | ||
| Pathogens | 389 | ||
| Clinical findings | 390 | ||
| Management | 390 | ||
| INFECTIOUS COMPLICATIONS OF GASTROINTESTINAL CANCERS | 390 | ||
| Colorectal Cancer | 390 | ||
| Epidemiology | 390 | ||
| Pathogens | 391 | ||
| Clinical findings | 391 | ||
| Management | 391 | ||
| COMPLICATED DISEASE AND UNUSUAL MANIFESTATIONS | 392 | ||
| Hepatobiliary Cancer | 392 | ||
| Epidemiology | 392 | ||
| Pathogens | 393 | ||
| Clinical manifestations | 393 | ||
| Management | 394 | ||
| Pancreatic Cancer | 394 | ||
| Gastroesophageal Cancers | 394 | ||
| Epidemiology | 394 | ||
| Pathogens | 395 | ||
| Clinical manifestations | 395 | ||
| Management | 395 | ||
| REFERENCES | 395 | ||
| Chemotherapy Complications | 400 | ||
| DEFINITIONS | 401 | ||
| DRUG INTERACTIONS AND TOXICITY | 401 | ||
| CHEMOTHERAPY TOXICITIES | 402 | ||
| GASTROINTESTINAL TOXICITIES | 402 | ||
| Nausea and Vomiting | 402 | ||
| Diarrhea | 403 | ||
| Mucositis | 405 | ||
| Prevention | 405 | ||
| Treatment | 405 | ||
| MYELOSUPPRESSION | 405 | ||
| CARDIOVASCULAR TOXICITY | 406 | ||
| PULMONARY TOXICITY | 407 | ||
| HEPATOTOXICITY | 408 | ||
| NEPHROTOXICITY | 409 | ||
| NEUROTOXICITY | 409 | ||
| COGNITIVE | 410 | ||
| CLINICAL GUIDELINES | 410 | ||
| PERFORMANCE IMPROVEMENT | 410 | ||
| REFERENCES | 411 | ||
| Malignant Bowel Obstruction in Advanced Cancer | 413 | ||
| DEFINITION | 414 | ||
| EPIDEMIOLOGY | 414 | ||
| PATHOPHYSIOLOGY | 414 | ||
| DIAGNOSIS | 415 | ||
| PROGNOSIS IN ADVANCED CANCER | 416 | ||
| MANAGEMENT | 417 | ||
| COMPLICATIONS | 420 | ||
| SUPPORTIVE MEASURES | 420 | ||
| DISCHARGE PLANNING | 422 | ||
| PERFORMANCE IMPROVEMENT | 422 | ||
| CLINICAL GUIDELINES | 422 | ||
| REFERENCES | 422 | ||
| Tumor Lysis Syndrome | 425 | ||
| DEFINITIONS | 426 | ||
| UNDERSTANDING EPIDEMIOLOGY HELPS WITH RISK ASSESSMENT, AND THUS MANAGEMENT | 428 | ||
| MANAGEMENT | 429 | ||
| PERFORMANCE IMPROVEMENT | 436 | ||
| CLINICAL GUIDELINES | 436 | ||
| REFERENCES | 436 | ||
| Principles of Radiation Therapy | 439 | ||
| BACKGROUND | 440 | ||
| CLINICAL GUIDELINES | 441 | ||
| MANAGEMENT OF RADIATION TOXICITY | 443 | ||
| Upper Gastrointestinal (Oral Mucositis and Esophagitis) | 444 | ||
| Lower Gastrointestinal (Enteritis) | 445 | ||
| GUIDELINES | 446 | ||
| PRACTICE IMPROVEMENT | 446 | ||
| REFERENCES | 447 | ||
| Metastatic Spinal Cord Compression | 452 | ||
| DEFINITION | 453 | ||
| EPIDEMIOLOGY | 453 | ||
| CLINICAL PRESENTATION | 454 | ||
| PROGNOSIS | 455 | ||
| Ambulatory Status | 455 | ||
| Tumor Histology | 455 | ||
| DIAGNOSIS | 456 | ||
| TREATMENT | 457 | ||
| Other Pharmacologic Treatment Options | 458 | ||
| Radiation Therapy | 459 | ||
| Surgery | 460 | ||
| PERFORMANCE IMPROVEMENT | 463 | ||
| CLINICAL GUIDELINES | 463 | ||
| ACKNOWLEDGMENT | 463 | ||
| REFERENCES | 463 |